Global Malaria Vaccines Market - 2022-2029

Global Malaria Vaccines Market - 2022-2029

Market Overview

Malaria Vaccines Market size was valued at US$ 33.29 million in 2021 and is estimated to reach US$ 327.41 million by 2029, growing at a CAGR of 31.85% during the forecast period (2022-2029).

Malaria an intermittent and remittent fever caused by a protozoan parasite that invades the red blood cells and is transmitted by mosquitoes in many tropical and subtropical regions and leads to severe illness in both pediatrics and adults. Malaria often causes severe disease, including shivering chills, high fevers, and flu-like symptoms. Humans are infected by four different types of malaria parasites Plasmodium falciparum, species of Anopheles, P. ovale, P. vivax, and P. malaria. Malaria vaccines are considered amongst the most important modalities for the prevention of malaria disease and the reduction of malaria transmission.

Market Dynamics

The major driving forces are the rising incidence of malaria cases, increase in research and development by various biotechnology or pharmaceutical companies and increasing government initiatives for malaria vaccines awareness are expected to drive market growth.

The rising incidences of malaria globally is expected to drive the market growth

The rising incidences of malaria cases globally are boosting the market over the forecast period. For instance, according to the World Health Organisation, around 241 million cases were observed globally out of which 6,27,000 deaths were recorded in 2022. African region again shows highest malaria burden share globally in 2020, 95% malaria cases with around 96% deaths were accounted by this region. In sub-Saharan Africa, it continues to be greatest cause of sickness and mortality in children as it claims around 260,000 lifes of African kids every year with age around 5 years or below.

The most recent recombinant vaccine to be created was RTS,S, which was created by GlaxoSmithKline (GSK) and Malaria Vaccine Initiatives (MVI) with funding from the the Gates Family Foundation. The vaccine is the 1st malaria vaccine to be recommended for ""wide use"" in children by World Health Organization in October 2021.

R21/Matrix-M is currently the most efficient malaria vaccine, with first studies showing 77% efficacy. This is the first vaccination that satisfies the WHO's requirement for a malaria vaccine to have at least a 75% effectiveness rate. The University of Oxford, London School of Hygiene and Tropical Medicine, Kenya Medical Research Institute, Serum Institute of India, Novavax and Institute of Research in Health Sciences in Nanoro, Burkina Faso collaborated to create it. Compared to the RTS,S vaccine, this R21 vaccine utilizes a larger proportion of the circumsporozoite protein (CSP) antigen.

The limitations associated with the malaria vaccines production will hamper the growth of the market

The scarcity of developers, traditional market's lack and the technical difficulty of creating a vaccine counter parasite can be the challenges for the production of a malaria vaccine. In October 2021 the Centre for diseaese control and prevention published a report where they stated that “The genetic complexity of malaria parasites results in thousands of possible antigens. Encounter with plasmodium parasites does not provide lifetime immunity, in contrast to diseases for which there are already effective vaccinations.” Therefore, from the above statements, the market is expected to get hampered in the forecast period.

Segment Analysis

The plasmodium falciparum segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The plasmodium falciparum segment is expected to boost the global malaria vaccine market, owing to the increased number of incidences leading to growing research activities. Due to the high incidence by Plasmodium falciparum malaria infection cases, it is anticipated to maintain a dominating position in the worldwide malaria vaccines market in forecasr period. For instance, plasmodium falciparum infection is responsible for more than 90% of malaria fatality worldwide, according to data from the National Center for Biotechnology Information published in August 2021, and thus continues to pose a serious threat to public health on a global scale. RTS,S/AS01 is the potential vaccine for P. falciparum malaria prevention that has undergone the most extensive testing; it targets immune responses against primary circumsporozoite protein (PfCSP) that covers the infecting sporozoite's surface.

Geographical Analysis

North America region holds the largest market share of the global malaria vaccines market

North America dominates the market for malaria vaccine and is expected to show a similar trend over the forecast period owing to the rising incidences of malaria and the rapid research and development of innovative, advanced vaccines development for malaria. According to Pan America Health Organization (PAHO) report 2022, around 600,000 cases of malaria were reported in 2020 by 18 endemic American countries. That shows reduction of 26% from last year. In 2018 Paraguay, got malaria-free certification and El Salvador also received malaria-free certification in 2021.

Ongoing research and development activities are expected to boost the market. For instance, in Dec 2021, VLP Therapeutics Inc., biotech company that is based in United States collaborated for infectious disease vaccination manufacturing and distribution with Nobelpharma Ltd.

Competitive Landscape

The malaria vaccines market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Major key players in malaria vaccines market are GlaxoSmithKline Biologicals (GSK), the Swiss Serum Institute, WRAIR, Sanaria, BioNTech, Nobelpharma, CellFree Sciences, Sumaya Biotech, VLP Therapeutics LLC, Bharat Biotech, Serum Institute of India, Novavax, Kenya medical research institute. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Malaria Vaccines market globally. For instance, in Sep 2021, Serum Institute of India subsidiary, Serum Institute Life Sciences announced its alliance with Biocon Biologics Limited. Under this alliance they will manufacture and commercialize variety of vaccines and antibodies targeting infectious diseases.

In Jun, 2022, BioNTech announced the initiation of construction of its first African facility for manufacturing of m-RNA Vaccine. They will manufacture m-RNA vaccines along with the development of malaria vaccine candidate.

GlaxoSmithKline Biologicals:

Overview:

GSK is a multinational biopharmaceutical business with the aspiration and mission to combine talent, science, and technology in order to conquer disease. They concentrate on four treatment fields: cancer, immunology, oncological disorders, and HIV. Prioritizing vaccination and specialty drug innovation will maximize the growing prospects for disease prevention and treatment.

Product Portfolio:

RTS, S/AS01 (Mosquirix): This is a recombinant vaccine for malaria that was created utilizing DNA from outer glycoprotein of the malaria parasite known as P. falciparum, a part of the hepatitis B virus, and an adjuvant to stimulate the immune system. Mosquirix is its name for commercial purpose. Elevated antibody titers that stop the parasite from invading the liver and helps to avoid infection.

Key Developments: In Oct 2021, Mosquirix vaccine became the first malarial vaccine to be recommended for ""wide use"" in children by World Health Organization.

The global malaria vaccines market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.